Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects

SALT LAKE CITY, Feb. 14, 2019 -- (Healthcare Sales & Marketing Network) -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated that the Phase 2 clinical stu... Biopharmaceuticals, FDA Lipocine, non-alcoholic steatohepatitis, LPCN 1144
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news